Please Wait
Applying Filters...
menu
    • menu
    J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

    Data Compilation
    #PharmaFlow

    Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

    Stock Recap
    #PipelineProspector

    Menu

    Exenatide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    CLINICAL TRIALS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,900,432Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    28/06/2025 TAPI Technology & API Services
    Israel
    		 TAPI NL BV 27123 EXENATIDE 2013-07-07 Active II Complete 2013-08-19 2013-05-09
    28/06/2025 ALP Pharm
    China
    		 ALP PHARM BEIJING CO LTD 35476 EXENATIDE 2020-12-15 Active II N/A